Literature DB >> 26124313

Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation.

Simone Carotti1, Umberto Vespasiani-Gentilucci2, Giuseppe Perrone3, Antonio Picardi2, Sergio Morini1.   

Abstract

AIMS: We investigated whether portal tract inflammation observed in non-alcoholic fatty liver disease (NAFLD) is associated with hepatic progenitor cell compartment activation, as thoroughly evaluated with different markers of the staminal lineage.
METHODS: Fifty-two patients with NAFLD were studied. NAFLD activity score, fibrosis and portal inflammation were histologically evaluated. Putative hepatic progenitor cells, intermediate hepatobiliary cells and bile ductules/interlobular bile ducts were evaluated by immunohistochemistry for cytokeratin (CK)-7, CK-19 and epithelial cell adhesion molecule (EpCAM), and a hepatic progenitor cell compartment score was derived. Hepatic stellate cell and myofibroblast activity was determined by immunohistochemistry for α-smooth muscle actin.
RESULTS: Portal inflammation was absent in a minority of patients, mild in 40% of cases and more than mild in about half of patients, showing a strong correlation with fibrosis (r=0.76, p<0.001). Portal inflammation correlated with CK-7-counted putative hepatic progenitor cells (r=0.48, p<0.001), intermediate hepatobiliary cells (r=0.6, p<0.001) and bile ductules/interlobular bile ducts (r=0.6, p<0.001), and with the activity of myofibroblasts (r=0.5, p<0.001). Correlations were confirmed when elements were counted by immunostaining for CK-19 and EpCAM. Lobular inflammation, ballooning, myofibroblast activity and hepatic progenitor cell compartment activation were associated with portal inflammation by univariate analysis. In the multivariate model, the only variable independently associated with portal inflammation was hepatic progenitor cell compartment activation (OR 3.7, 95% CI 1.1 to 12.6).
CONCLUSIONS: Portal inflammation is frequent during NAFLD and strongly associated with activation of putative hepatic progenitor cells since the first steps of their differentiation, portal myofibroblast activity and fibrosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  IMMUNOHISTOCHEMISTRY; LIVER DISEASE; fibrosis

Mesh:

Year:  2015        PMID: 26124313     DOI: 10.1136/jclinpath-2014-202717

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  6 in total

1.  A Novel Pathological Scoring System for Hepatic Cirrhosis with Hepatocellular Carcinoma.

Authors:  Wei Dong; Hua Yu; Yu-Yao Zhu; Zhi-Hong Xian; Jia Chen; Hao Wang; Chun-Chao Shi; Guang-Zhi Jin; Hui Dong; Wen-Ming Cong
Journal:  Cancer Manag Res       Date:  2020-07-08       Impact factor: 3.989

2.  Starring role of toll-like receptor-4 activation in the gut-liver axis.

Authors:  Simone Carotti; Michele Pier Luca Guarino; Umberto Vespasiani-Gentilucci; Sergio Morini
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 3.  Diabetic fibrosis.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-12-28       Impact factor: 5.187

4.  Reelin expression in human liver of patients with chronic hepatitis C infection.

Authors:  Simone Carotti; Giuseppe Perrone; Michelina Amato; Umberto Vespasiani Gentilucci; Daniela Righi; Maria Francesconi; Claudio Pellegrini; Francesca Zalfa; Maria Zingariello; Antonio Picardi; Andrea Onetti Muda; Sergio Morini
Journal:  Eur J Histochem       Date:  2017-03-17       Impact factor: 3.188

5.  Vascular Endothelial Growth Factor Promotes Proliferation of Epithelial Cell Adhesion Molecule-Positive Cells in Nonalcoholic Steatohepatitis.

Authors:  Hamda Siddiqui; Preety Rawal; Chaggan Bihari; Naveen Arora; Savneet Kaur
Journal:  J Clin Exp Hepatol       Date:  2019-12-10

6.  The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio Picardi
Journal:  Arch Med Sci       Date:  2016-03-23       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.